US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

DOR

Dor (DOR)

Dor Biopharma

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:DOR

1

Fecha	Hora	Fuente	Título	Símbolo	Compañía
07/04/2006	08:19	Business Wire	DOR BioPharma Announces Advances in Mucosal Vaccines for Botulinum Toxin; Antigens are Made Using Dowpharma's Pfenex Expression	AMEX:DOR	Dor Biopharma
06/04/2006	14:28	Business Wire	DOR BioPharma Announces Private Equity Financing of $3.65 Million with Institutional Investors	AMEX:DOR	Dor Biopharma
30/03/2006	08:00	Business Wire	DOR BioPharma Reports Year End 2005 Financial Results and Accomplishments; DOR Provides Guidance on Regulatory Filings on orBec	AMEX:DOR	Dor Biopharma
08/02/2006	08:25	Business Wire	DOR BioPharma Provides Financial Guidance and Update on European Regulatory Plans for orBec(R)	AMEX:DOR	Dor Biopharma
30/01/2006	16:48	Business Wire	DOR BioPharma Announces Positive Phase I Results of RiVax(TM), its Vaccine Against Ricin Toxin; Vaccine is Immunogenic and Well	AMEX:DOR	Dor Biopharma
25/01/2006	09:31	Business Wire	DOR BioPharma Achieves Manufacturing Milestone in Development of RiVax(TM); DOR and Its Collaborators Achieve 2nd Milestone Ahea	AMEX:DOR	Dor Biopharma
20/01/2006	07:10	Business Wire	DOR BioPharma Reports Positive New Survival Findings from Previously Completed Phase II and III Clinical Trials of orBec(R); Res	AMEX:DOR	Dor Biopharma
19/01/2006	08:26	Business Wire	DOR BioPharma Secures $6 Million Equity Commitment from Fusion Capital	AMEX:DOR	Dor Biopharma
15/11/2005	08:04	Business Wire	DOR BioPharma Plans FDA NDA and European MAA Filing Strategy for orBec	AMEX:DOR	Dor Biopharma
14/11/2005	15:26	Business Wire	DOR BioPharma Inc. Reports Third Quarter 2005 Financial Results and Reviews Recent Achievements; Conference Call Scheduled for N	AMEX:DOR	Dor Biopharma
07/11/2005	06:00	Business Wire	DOR BioPharma to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference	AMEX:DOR	Dor Biopharma
02/11/2005	05:00	Business Wire	DOR BioPharma Executes Letter of Intent for Acquisition of Gastrotech Pharma; Acquisition Bolsters Biotherapeutics Pipeline	AMEX:DOR	Dor Biopharma
01/11/2005	15:34	Business Wire	DOR BioPharma Receives Notice of Delisting from American Stock Exchange; Company to Continue to Negotiate Potential Compliance-A	AMEX:DOR	Dor Biopharma
14/10/2005	08:17	Business Wire	DOR BioPharma Provides Update on Programs and Corporate Matters	AMEX:DOR	Dor Biopharma
15/09/2005	16:41	PR Newswire (US)	Dr. Chris Dale, Vice President, Technology, Cambrex Biopharmaceuticals and Dr. Robert N. Brey, Chief Scientific Officer, DOR Bio	AMEX:DOR	Dor Biopharma
26/07/2005	12:07	PR Newswire (US)	DOR BioPharma and Dowpharma Enter Into a Joint Development Agreement for BT-VACC(TM), DOR's Oral Vaccine Against Botulinum Toxin	AMEX:DOR	Dor Biopharma
15/06/2005	05:30	Business Wire	DOR BioPharma, Inc. Announces Positive Interim Results from Phase I Clinical Trial of RiVax, Its Ricin Toxin Vaccine	AMEX:DOR	Dor Biopharma
13/06/2005	10:14	Business Wire	DOR BioPharma to Present at the Rodman & Renshaw Techvest 2nd Annual Security and Connectivity Conference	AMEX:DOR	Dor Biopharma
04/05/2005	09:51	Business Wire	DOR BioPharma to Present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference	AMEX:DOR	Dor Biopharma
04/05/2005	07:30	Business Wire	DOR BioPharma Appoints T. Jerome Madison to Board of Directors	AMEX:DOR	Dor Biopharma
07/01/2005	07:30	PR Newswire (US)	DOR BioPharma and Cambrex Enter into a Development and Manufacturing Process Agreement for RiVax(TM)	AMEX:DOR	Dor Biopharma

Showing the most relevant articles for your search:AMEX:DOR

1

JP Morgan Chase

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

US Dollar vs MXN

Gold vs US Dollar

Energy Select Sector SPDR

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones